Paxalisib
Glioblastoma (GBM)
Key Facts
About Kazia Therapeutics
Kazia Therapeutics is a clinical-stage Australian biotech company dedicated to developing novel cancer therapies, with a core focus on aggressive brain cancers. Its lead asset, paxalisib, is a PI3K/mTOR inhibitor that has received Orphan Drug and Fast Track Designations from the FDA for glioblastoma and is in pivotal-stage development. The company's pipeline also includes EVT801, a VEGFR3 inhibitor in Phase 1 for solid tumors. As a publicly listed entity on the ASX, Kazia operates as a pre-revenue company, relying on capital markets and partnerships to fund its clinical programs.
View full company profileAbout Kazia Therapeutics
Kazia Therapeutics is a clinical-stage Australian biotech company dedicated to developing novel cancer therapies, with a core focus on aggressive brain cancers. Its lead asset, paxalisib, is a PI3K/mTOR inhibitor that has received Orphan Drug and Fast Track Designations from the FDA for glioblastoma and is in pivotal-stage development. The company's pipeline also includes EVT801, a VEGFR3 inhibitor in Phase 1 for solid tumors. As a publicly listed entity on the ASX, Kazia operates as a pre-revenue company, relying on capital markets and partnerships to fund its clinical programs.
View full company profileTherapeutic Areas
Other Glioblastoma (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| DB102 (Enzastaurin) | Denovo Biopharma | Phase 3 |
| GlioGuard Therapeutic & Diagnostic System | GlioGuard | Pre-clinical |
| DOC1021 | Diakonos Oncology | Phase 2 |